Javascript must be enabled to continue!
The Effects of Nocturnal Acid Breakthrough on Helicobacter pylori Eradication
View through CrossRef
ABSTRACTBackground. The effects of nocturnal gastric acid breakthrough (NAB) on Helicobacter pylori eradication are still unknown in peptic ulcer patients. The purposes of this study were to compare the effect of lansoprazole 30 mg twice a day (bid) to lansoprazole 60 mg once a day (qd) on the prevalence of NAB, and to determine whether NAB affects the eradication of H. pylori in peptic ulcer patients.Methods. Experiments were carried out in 67 patients with H. pylori‐positive peptic ulcers. They were randomized into two groups, one treated with a combination of lansoprazole 60 mg, clarithromycin 1.0 g, and amoxycillin 2.0 g once a day before breakfast (qd group), and the other, divided doses of the drugs were given before breakfast and dinner (bid group) for 2 weeks.Results. NAB occurred in 31 patients, 55.2% in qd group, and 39.5% in bid group (p = .226). H. pylori eradication was achieved in 61.3% in NAB positive group and 83.3% in NAB negative group (p = .055). The mean duration of NAB for H. pylori eradication group was 99.3 ± 22.7 min, and 293.2 ± 49.8 min for H. pylori persistence group (p < .05). The median intragastric pH of the H. pylori eradication and persistence group was 5.7 ± 0.2 and 4.2 ± 0.4, respectively (p < .05).Conclusions. Neither the morning dose and the divided dose regimen of lansoprazole affected the intragastric acidity and occurrence of the NAB. NAB did not influence H. pylori eradication in peptic ulcer patients, but the duration of NAB and total intragastric median pH were found to influence the H. pylori eradication.
Title: The Effects of Nocturnal Acid Breakthrough on Helicobacter pylori Eradication
Description:
ABSTRACTBackground.
The effects of nocturnal gastric acid breakthrough (NAB) on Helicobacter pylori eradication are still unknown in peptic ulcer patients.
The purposes of this study were to compare the effect of lansoprazole 30 mg twice a day (bid) to lansoprazole 60 mg once a day (qd) on the prevalence of NAB, and to determine whether NAB affects the eradication of H.
pylori in peptic ulcer patients.
Methods.
Experiments were carried out in 67 patients with H.
pylori‐positive peptic ulcers.
They were randomized into two groups, one treated with a combination of lansoprazole 60 mg, clarithromycin 1.
0 g, and amoxycillin 2.
0 g once a day before breakfast (qd group), and the other, divided doses of the drugs were given before breakfast and dinner (bid group) for 2 weeks.
Results.
NAB occurred in 31 patients, 55.
2% in qd group, and 39.
5% in bid group (p = .
226).
H.
pylori eradication was achieved in 61.
3% in NAB positive group and 83.
3% in NAB negative group (p = .
055).
The mean duration of NAB for H.
pylori eradication group was 99.
3 ± 22.
7 min, and 293.
2 ± 49.
8 min for H.
pylori persistence group (p < .
05).
The median intragastric pH of the H.
pylori eradication and persistence group was 5.
7 ± 0.
2 and 4.
2 ± 0.
4, respectively (p < .
05).
Conclusions.
Neither the morning dose and the divided dose regimen of lansoprazole affected the intragastric acidity and occurrence of the NAB.
NAB did not influence H.
pylori eradication in peptic ulcer patients, but the duration of NAB and total intragastric median pH were found to influence the H.
pylori eradication.
Related Results
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
Background: Helicobacter pylori causes inflammation of the gastric mucosa and is associated with many upper gastrointestinal diseases, including chronic gastritis, peptic ulcer dis...
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Clinicopathological Characteristics and Endoscopic Features of Early Gastric Cancers Diagnosed After Helicobacter pylori Eradication
Abstract
Background. Helicobacter pylori (H. pylori) infection is an important risk factor for developing gastric cancer. However, even after H. pylori eradication, early g...
Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021
Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021
Abstract
Introduction: Infection with Helicobacter pylori is one of the most frequent chronic bacterial illnesses in humans, infecting more than half of the world's populat...
Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis.
Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis.
e16104
Background:
Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related death worldwide. One o...
Helicobacter pylori and gastric cancer
Helicobacter pylori and gastric cancer
Introduction: According to GLOBOCAN estimates for 2018, gastric cancer was the fifth most common cancer and the third most common cause of death from malignant diseases in the worl...
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Abstract
Eradication of Helicobacter pylori (H. pylori) infection in children is challenging due to increased antibiotic resistance and decreased effectiveness of the cur...

